Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00311532
Status:
COMPLETED
Last Update Posted:
2007-07-18
First Post:
2006-04-05
Brief Title:
Observational Study of Pergolide Mesylate and Cardiac Valvulopathy
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Observational Study to Determine the Incidence of New-Onset Valvulopathy in Patients Treated With Pergolide as Second-Line Therapy for Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2007-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to estimate the incidence of new-onset valvulopathy determined by baseline and follow-up echocardiograms in patients with Parkinsons Disease who are receiving pergolide as second-line therapy
The secondary objective of the study is to estimate the prevalence of valvulopathy as determined by baseline echocardiograms among all patients who have Parkinsons Disease and are being considered for pergolide as second-line therapy
The secondary objective of the study is to estimate the prevalence of valvulopathy as determined by baseline echocardiograms among all patients who have Parkinsons Disease and are being considered for pergolide as second-line therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B4G-MC-B001 | None | None | None |